EarCentric EX2 vs Otofonix Groove

The EarCentric EX2 is a budget-priced prescription behind-the-ear hearing aid released in 2021, earning a C grade with a SoundScore of 2.7/5 in HearAdvisor's lab testing. At $218, it ranks #33 of 36 prescription hearing aids tested, placing it in the bottom 11% of its category. In our testing, the EX2 showed a significant split in performance. Feedback handling was excellent at 4.7/5, essentially matching the category average and demonstrating stable operation during movement. However, speech performance was notably limited, with both speech in quiet and speech in noise scoring 1.0/5—well below the category averages of 3.32 and 1.96 respectively. Music streaming scored 0.0/5, falling 2.64 points below the prescription category average of 2.64/5. Own-voice comfort scored 2.3/5, a mixed result that sits 0.45 points below the category average. The device uses a rechargeable battery, which adds convenience for daily use. Notably, tuning did not improve performance in our testing—the Initial and Tuned fit scores were identical at 2.7/5. Budget-conscious shoppers in this price range may want to compare alternatives. The RxEars Rxi scored 4.09/5 at a similar price point, while OTC options like the Audien Hearing Atom offer comparable or better sound performance at lower prices. The EX2 may suit users who prioritize feedback stability and rechargeable convenience over speech clarity, but its limited speech performance is a significant tradeoff.

The Otofonix Groove is a behind-the-ear prescription hearing aid priced at $795, earning a C grade with a SoundScore of 2.7/5 in our lab testing. This rechargeable BTE device ranks 36th out of 36 tested prescription hearing aids, placing it in the bottom tier of its category. In our testing, the Groove demonstrated one clear strength: excellent feedback handling at 5.0/5, scoring 0.29 points above the category average. The device remained stable during our standardized challenge motions with no audible feedback issues. However, speech performance was significantly limited, with both speech in quiet and speech in noise scoring 1.0/5—falling 2.32 and 0.96 points below their respective category averages. Music streaming quality scored 0.0/5, which is 2.64 points below the prescription category average. Own-voice comfort was also low at 0.4/5 in the tuned configuration, 2.35 points below average, suggesting notable occlusion-related concerns. The normalized Initial Score of 2.7/5 and Tuned Score of 2.6/5 indicate that professional fitting adjustments did not improve overall performance. Given its positioning at the bottom of the prescription hearing aid category and the availability of lower-priced alternatives that scored higher in our testing, the Otofonix Groove may be difficult to recommend for most users seeking balanced sound quality across listening situations.